Dr. Carla Falkson is the Director of the Breast Oncology Clinical Research Program and Breast Cancer Service Line at the UR Medicine Wilmot Cancer Institute. She is also the Medical Director of Pluta Cancer Center.

Dr. Falkson's research is focused on developing innovative treatments for pat...

Faculty Appointments

Professor - Department of Medicine, Hematology/Oncology (SMD)

Credentials

Residency & Fellowship

Fellowship, Hematology & Oncology, Steve Biko Academic Hospital of Pretoria (South Africa). 1989 - 1994

Fellowship, Medical Oncology, University of Texas MD Anderson Cancer Center. 1986 - 1987

Residency, Hematology & Oncology, Steve Biko Academic Hospital of Pretoria (South Africa). 1983 - 1989

Internship, Kalafong Hospital Pretoria (South Africa). 1982 - 1983

Education

MBBCH | University Of Pretoria (South Africa). 1982

Awards

Unsung Hero Award. 2018

Directory Listing. 2013 - 2017

Directory Listing. 2012 - 2013

Directory Listing. 2012

Directory Listing. 2000 - 2001

Directory Listing. 2000

Research Committee Merit Certificate for outstanding article in all categories. 1999

ECOG Statistical Center Award for Excellence in Data Management. 1998

Sister Joan Award for Outstanding Achievement and Service to the Community. 1997

ECOG Statistical Center Award for Excellence in Quality of Data. 1996

Eastern Cooperative Oncology Group award for best Quality of Life Evaluations submitted. 1996

Women's Directory. 1995

Directory Listing. 1995

"MER-National" prize for article. 1984

H W Snyman Preventive Medicine prize. 1981

Merit Award for Outstanding Academic Achievement. 1981

Merit Award for Outstanding Academic Achievement. 1980

Merit Award for Outstanding Academic Achievement;. 1979

Physiology Prize. 1979

Virology Prize. 1979

H W Snyman Award for Outstanding Achievement. 1979

Merit Award for Outstanding Academic Achievement. 1978

Merit Award for Outstanding Academic Achievement. 1977

Research

Clinical Trials

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)

Lead Researcher: Carla Falkson

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, ...

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence

Lead Researcher: Carla Falkson

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participa...

Publications

Journal Articles

Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer.

Neupane N, Bawek S, Gurusinghe S, Ghaffary EM, Mirmosayyeb O, Thapa S, Falkson C, O'Regan R, Dhakal A

Cancers.. 2024 January 3116 (3)Epub 01/31/2024.

A Pilot Study of the Combination of Entinostat with Capecitabine in Advanced Breast Cancer.

Millard T, Brenin C, Humphrey C, Dhakal A, Falkson C, Petroni G, Wages NA, Dillon P

International journal of breast cancer.. 2024 2024 :5515966. Epub 02/07/2024.

Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials: A Secondary Analysis of NRG Oncology Randomized Clinical Trials.

Hallemeier CL, Moughan J, Haddock MG, Herskovic AM, Minsky BD, Suntharalingam M, Zeitzer KL, Garg MK, Greenwald BD, Komaki RU, Puckett LL, Kim H, Lloyd S, Bush DA, Kim HE, Lad TE, Meyer JE, Okawara GS, Raben A, Schefter TE, Barker JL, Falkson CI, Videtic GMM, Jacob R, Winter KA, Crane CH

JAMA network open.. 2023 April 36 (4):e238504. Epub 04/03/2023.

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.

Parsons HA, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson VG, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina TA, Carey LA, Rimawi MF, Miller KD, Stearns V, Specht J, Falkson C, Burstein HJ, Wolff AC, Winer EP, Tayob N, Krop IE, Makrigiorgos GM, Golub TR, Mayer EL, Adalsteinsson VA

medRxiv : the preprint server for health sciences.. 2023 March 8 Epub 03/08/2023.

Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer.

Peddi PF, Fasching PA, Liu D, Quinaux E, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Cunningham JM, Weinshilboum RM, Pienkowski T, Eiermann W, Martín M, Bee V, Wang X, Wang L, Yang E, Slamon DJ, Hurvitz SA

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2022 May 228 (9):1854-1862. Epub 1900 01 01.

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.

Schneider BP, Jiang G, Ballinger TJ, Shen F, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Hancock BA, Kassem N, Helft P, O'Neil B, Storniolo AMV, Badve S, Miller KD, Radovich M

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2022 February 140 (4):345-355. Epub 12/15/2021.

Adjuvant tamoxifen adherence in male patients with breast cancer: An ongoing challenge.

Falkson CI

Cancer.. 2022 January 1128 (1):22-24. Epub 10/01/2021.

Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report.

Kharel Z, Nemer OP, Xi W, Upadhayaya B, Falkson CI, O'Regan RM, Dhakal A

Breast disease.. 2022 41 (1):255-260. Epub 1900 01 01.

Erratum to: Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report.

Kharel Z, Nemer OP, Xi W, Upadhayaya B, Falkson CI, O'Regan RM, Dhakal A

Breast disease.. 2022 41 (1):363. Epub 1900 01 01.

Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.

Hamilton EP, Kaklamani V, Falkson C, Vidal GA, Ward PJ, Patre M, Chui SY, Rotmensch J, Gupta K, Molinero L, Li Y, Emens LA

Clinical breast cancer.. 2021 December 21 (6):539-551. Epub 05/15/2021.

PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer.

Dhakal A, Acharya L, O'Regan R, Gandhi S, Falkson C

International journal of molecular sciences.. 2021 November 222 (21)Epub 11/02/2021.

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.

Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ

NPJ breast cancer.. 2021 October 57 (1):131. Epub 10/05/2021.

Adjuvant cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive breast cancer: One Monarch to rule them all?

Dhakal A, Falkson C, O'Regan RM

Cancer.. 2021 September 15127 (18):3302-3309. Epub 05/28/2021.

Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307).

Kizub DA, Miao J, Schubert MM, Paterson AHG, Clemons M, Dees EC, Ingle JN, Falkson CI, Barlow WE, Hortobagyi GN, Gralow JR

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.. 2021 May 29 (5):2509-2517. Epub 09/15/2020.

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.

Stringer-Reasor EM, May JE, Olariu E, Caterinicchia V, Li Y, Chen D, Della Manna DL, Rocque GB, Vaklavas C, Falkson CI, Nabell LM, Acosta EP, Forero-Torres A, Yang ES

Breast cancer research : BCR.. 2021 March 423 (1):30. Epub 03/04/2021.

Less Toxic Chemotherapy in Locally Advanced Breast Cancer.

Carpenter J, Forero A, Falkson CI, Nabell LM, De Los Santos JF, Krontiras H, Bland KI, Li Y, Bae S

Southern medical journal.. 2020 November 113 (11):559-563. Epub 1900 01 01.

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.

Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, Paplomata E, Walling R, Daily K, Mahtani R, Thompson MA, Graham R, Cooper ME, Pavlick DC, Albacker LA, Gregg J, Solzak JP, Chen YH, Bales CL, Cantor E, Shen F, Storniolo AMV, Badve S, Ballinger TJ, Chang CL, Zhong Y, Savran C, Miller KD, Schneider BP

JAMA oncology.. 2020 September 16 (9):1410-1415. Epub 1900 01 01.

Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer.

Moftakhar B, Lekkala M, Strawderman M, Smith TC, Meacham P, Fitzgerald B, Falkson CI, Dhakal A

Breast cancer research and treatment.. 2020 September 183 (2):411-418. Epub 07/15/2020.

Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.

Gralow JR, Barlow WE, Paterson AHG, M'iao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN

Journal of the National Cancer Institute.. 2020 July 1112 (7):698-707. Epub 1900 01 01.

Neratinib-Induced Duodenal Ulcer: A Case Report.

Moftakhar B, Kharel P, Niraula S, Gandhi S, Falkson C, Dhakal A

Breast cancer : basic and clinical research.. 2020 14 :1178223420935871. Epub 06/23/2020.

Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.

Borges VF, Ferrario C, Aucoin N, Falkson C, Khan Q, Krop I, Welch S, Conlin A, Chaves J, Bedard PL, Chamberlain M, Gray T, Vo A, Hamilton E

JAMA oncology.. 2018 September 14 (9):1214-1220. Epub 1900 01 01.

Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.

Royce M, Bachelot T, Villanueva C, Özgüroglu M, Azevedo SJ, Cruz FM, Debled M, Hegg R, Toyama T, Falkson C, Jeong J, Srimuninnimit V, Gradishar WJ, Arce C, Ridolfi A, Lin C, Cardoso F

JAMA oncology.. 2018 July 14 (7):977-984. Epub 1900 01 01.

Accuracy of Medicare Claim-based Algorithm to Detect Breast, Prostate, or Lung Cancer Bone Metastases.

Sathiakumar N, Delzell E, Yun H, Jooste R, Godby K, Falkson C, Yong M, Kilgore ML

Medical care.. 2017 December 55 (12):e144-e149. Epub 1900 01 01.

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF,

The New England journal of medicine.. 2017 November 9377 (19):1836-1846. Epub 1900 01 01.

A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).

Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW

Breast cancer research and treatment.. 2017 September 165 (2):375-382. Epub 06/16/2017.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA,

The New England journal of medicine.. 2016 July 7375 (1):11-22. Epub 1900 01 01.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ,

The New England journal of medicine.. 2016 July 7375 (1):23-34. Epub 1900 01 01.

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697).

Lawson DH, Lee S, Zhao F, Tarhini AA, Margolin KA, Ernstoff MS, Atkins MB, Cohen GI, Whiteside TL, Butterfield LH, Kirkwood JM

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2015 December 133 (34):4066-76. Epub 09/08/2015.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Lancet.. 2015 October 3386 (10001):1341-1352. Epub 07/23/2015.

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).

Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2015 August 2033 (24):2623-31. Epub 07/13/2015.

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

, McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S

Lancet.. 2014 June 21383 (9935):2127-35. Epub 03/19/2014.

Mortality following bone metastasis and skeletal-related events among patients 65 years and above with lung cancer: A population-based analysis of U.S. Medicare beneficiaries, 1999-2006.

Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, Blackburn J, Arora T, Kilgore ML

Lung India : official organ of Indian Chest Society.. 2013 January 30 (1):20-6. Epub 1900 01 01.

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.

Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, Weir LM, Brufsky AM, Dakhil S, Lad T, Baez-Diaz L, Gralow JR, Robidoux A, Perez EA, Zheng P, Geyer CE, Swain SM, Costantino JP, Mamounas EP, Wolmark N

The Lancet. Oncology.. 2012 July 13 (7):734-42. Epub 06/14/2012.

Analysis of Fc? receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.

Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM

Clinical cancer research : an official journal of the American Association for Cancer Research.. 2012 June 1518 (12):3478-86. Epub 04/13/2012.

Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006.

Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, Blackburn J, Arora T, Brill I, Kilgore ML

Breast cancer research and treatment.. 2012 January 131 (1):231-8. Epub 08/13/2011.

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.

, Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R

Lancet.. 2011 November 12378 (9804):1707-16. Epub 10/19/2011.

Adjuvant trastuzumab in HER2-positive breast cancer.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J,

The New England journal of medicine.. 2011 October 6365 (14):1273-83. Epub 1900 01 01.

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

, Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R

Lancet.. 2011 August 27378 (9793):771-84. Epub 07/28/2011.

Exemestane for breast-cancer prevention in postmenopausal women.

Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H,

The New England journal of medicine.. 2011 June 23364 (25):2381-91. Epub 06/04/2011.

Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006.

Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V, Blackburn J, Arora T, Kilgore ML

Prostate cancer and prostatic diseases.. 2011 June 14 (2):177-83. Epub 03/15/2011.

Phase II Trial of Docetaxel and Carboplatin in Patients With Advanced Squamous Carcinoma of the Esophagus (E2298): A Trial of the Eastern Cooperative Oncology Group.

Rossman JF, Falkson CI, Xu R, Slabber CF, Mason BA, Mulcahy MF, Benson AB

Gastrointestinal cancer research : GCR.. 2011 January 4 (1):9-14. Epub 1900 01 01.

Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.

Forero-Torres A, Saleh MN, Galleshaw JA, Jones CF, Shah JJ, Percent IJ, Nabell LM, Carpenter JT, Falkson CI, Krontiras H, Urist MM, Bland KI, De Los Santos JF, Meredith RF, Caterinicchia V, Bernreuter WK, O'Malley JP, Li Y, LoBuglio AF

Clinical breast cancer.. 2010 August 110 (4):275-80. Epub 1900 01 01.

Phase II study of interleukin-4 in indolent B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E5Y92).

Wiernik PH, Dutcher JP, Yao X, Venkatraj U, Falkson CI, Rowe JM, Cassileth PA

Journal of immunotherapy.. 2010 33 (9):1006-9. Epub 1900 01 01.

Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.

, Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S

Journal of the National Cancer Institute. Monographs.. 2010 2010 (41):162-77. Epub 1900 01 01.

A Phase II Study of the Histone Deacetylase Inhibitor, Vorinostat, in Combination with Trastuzumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent HER-2 Amplified Breast Cancer Resistant to Trastuzumab-Containing Therapy: (E1104) a Trial of the Eastern Cooperative Oncology Group.

Swaby R;Wang M; Sparano J;Bhalla K, Meropol N; Falkson C; Pellegrino C; Klein P; Goldstein L;Sledge Jr G.

Cancer Research. 2009; 69(suppl 24).

An evidence-based systematic review of bilberry (Vaccinium myrtillus) by the Natural Standard Research Collaboration.

Ulbricht C, Basch E, Basch S, Bent S, Boon H, Burke D, Costa D, Falkson C, Giese N, Goble M, Hashmi S, Mukarjee S, Papaliodis G, Seamon E, Tanguay-Colucci S, Weissner W, Woods J

Journal of dietary supplements.. 2009 6 (2):162-200. Epub 1900 01 01.

Receipt of standard breast cancer treatment by African American and White women.

Worthington J, Waterbor JW, Funkhouser E, Falkson C, Cofield S, Fouad M

International journal of medical sciences.. 2008 July 75 (4):181-8. Epub 07/07/2008.

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.

, Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, Goldhirsch A, Gray R, Peto R, Pritchard KI, Wood WC

Lancet.. 2008 January 5371 (9606):29-40. Epub 1900 01 01.

Accuracy of registry breast cancer treatment data among cases treated in urban hospitals

Worthington J; Funkhouser E; Waterbor JW; Falkson C;Cofield S; Fouad M.

Journal of Registry Management. 2008; 35(2): 75-80.

Tumor exosomes inhibit differentiation of bone marrow dendritic cells.

Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L, Li C, Cong Y, Kimberly R, Grizzle WE, Falkson C, Zhang HG

The Journal of immunology : official journal of the American Association of Immunologists.. 2007 June 1178 (11):6867-75. Epub 1900 01 01.

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.

Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y,

Lancet.. 2005 December 17366 (9503):2087-106. Epub 1900 01 01.

A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma.

Biagi JJ, Herbert KE, Smith C, Abdi E, Leahy M, Falkson C, Wolf M, Januszewicz H, Seymour JF, Richards K, Matthews JP, Dale B, Prince HM

Leukemia & lymphoma.. 2005 February 46 (2):197-206. Epub 1900 01 01.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Lancet.. 2005 365 (9472):1687-717. Epub 1900 01 01.

Vinorelbine and cisplatin in advanced squamous cell carcinoma of the cervix: the South African experience.

Goedhals L, Falkson G, Smith BL, Falkson CI, Gasmi J, Lategan A, Burillon JP, His P

Anticancer research.. 2005 25 (3c):2489-92. Epub 1900 01 01.

A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96.

Wadler S, Levy D, Frederickson HL, Falkson CI, Wang Y, Weller E, Burk R, Ho G, Kadish AS,

Gynecologic oncology.. 2004 March 92 (3):957-64. Epub 1900 01 01.

The Treatment of Metastatic Breast Cancer: Overview

Falkson Carla I.

Medical Professional Magazine Alabama. 2004; 1(1).

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2003 March 1521 (6):968-75. Epub 1900 01 01.

Phase II Study of Ifosfamide+Doxorubicin in Patients With Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group.

Edmonson JH, Ryan LM, Falkson CI, Hicks DG, Blum RH

Sarcoma.. 2003 7 (1):9-11. Epub 1900 01 01.

Report on the 4th International Conference on the Adjuvant Therapy of Malignant Melanoma held at the Royal College of Physicians, London, UK, 15-16 March 2002.

Retsas S, Falkson C, Spitler L

Melanoma research.. 2002 June 12 (3):A1-4. Epub 1900 01 01.

Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93).

Schink JC, Weller E, Harris LS, Cella D, Gerstner J, Falkson C, Wadler S

The cancer journal.. 2001 7 (2):155-64. Epub 1900 01 01.

Absence of commonly recurring BRCA1 mutations in black South African women with breast cancer.

Yawitch TM, van Rensburg EJ, Mertz M, Falkson CI

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.. 2000 August 90 (8):788. Epub 1900 01 01.

Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196.

Sparano JA, O'Neill A, Schaefer PL, Falkson CI, Wood WC

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2000 June 18 (12):2369-77. Epub 1900 01 01.

21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature.

Saphner T, Weller EA, Tormey DC, Pandya KJ, Falkson CI, Stewart J, Robert NJ

American journal of clinical oncology.. 2000 June 23 (3):258-62. Epub 1900 01 01.

Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Lancet.. 2000 May 20355 (9217):1757-70. Epub 1900 01 01.

Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189.

Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, Gilchrist KW, Pandya KJ, Page DL, Robert NJ

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2000 May 18 (10):2059-69. Epub 1900 01 01.

Development of three African language translations of the FACT-G.

Mullin V, Cella D, Chang CH, Eremenco S, Mertz M, Lent L, Falkson C, Falkson G

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.. 2000 March 9 (2):139-49. Epub 1900 01 01.

Treatment of squamous cell esophageal cancer with topotecan: an Eastern Cooperative Oncology Group Study (E2293).

Asbury RF, Lipsitz S, Graham D, Falkson CI, Baez L, Benson AB

American journal of clinical oncology.. 2000 February 23 (1):45-6. Epub 1900 01 01.

Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials.

Early Breast Cancer Trialists' Collaborative Group.

Lancet. 2000; 355(9217): 1757-70.

Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study.

Sparano JA, Hu P, Rao RM, Falkson CI, Wolff AC, Wood WC

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 1999 December 17 (12):3828-34. Epub 1900 01 01.

A phase II evaluation of clofazimine plus doxorubicin in advanced, unresectable primary hepatocellular carcinoma.

Falkson CI, Falkson G

Oncology.. 1999 October 57 (3):232-5. Epub 1900 01 01.

Carcinoma of unknown primary site--leave it unknown.

McMichael GB, Falkson CI

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.. 1999 August 89 (8):844-5. Epub 1900 01 01.

Phase II trial of fludarabine and cyclophosphamide (Flu/Cy) in patients with previously untreated chronic lymphocytic leukemia: An eastern cooperative oncology group study (E1997)

Flinn IW; Lee S; Bennett JM; Falkson CI; Flynn P; Pundaleeka S; Stadtmauer E; Schnel.F; Tallman.M; Rowe.JM.

.BLOOD. 1999; 94(10): 4610.

A randomized study of radiotherapy alone versus radiotherapy plus 5-fluorouracil and platinum in patients with inoperable, locally advanced squamous cancer of the esophagus.

Slabber CF, Nel JS, Schoeman L, Burger W, Falkson G, Falkson CI

American journal of clinical oncology.. 1998 October 21 (5):462-5. Epub 1900 01 01.

Extended survival in 80 patients with operable, locoregionally recurrent breast cancer treated with chemotherapy.

Eek RW, Falkson CI

American journal of clinical oncology.. 1998 October 21 (5):501-4. Epub 1900 01 01.

Current treatment options for malignant melanoma.

Cohen GL, Falkson CI

Drugs.. 1998 June 55 (6):791-9. Epub 1900 01 01.

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.

Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 1998 May 16 (5):1743-51. Epub 1900 01 01.

Treatment of Melanoma.

Falkson C I; Cohen G L; Eek R W; Slabber C F.

Specialist Medicine. 1998; : 12-15, 28.

Prognostic factors in metastatic malignant melanoma. An analysis of 236 patients treated on clinical research studies at the Department of Medical Oncology, University of Pretoria, South Africa from 1972-1992.

Falkson CI, Falkson HC

Oncology.. 1998 55 (1):59-64. Epub 1900 01 01.

Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin.

Falkson CI, Cohen GL

Oncology.. 1998 55 (2):116-21. Epub 1900 01 01.

Hepatocellular carcinoma.

Falkson G, Falkson CI, Garbers LM

Cancer treatment and research.. 1998 98 :83-109. Epub 1900 01 01.

2nd International Conference on the Adjuvant Therapy of Malignant Melanoma. London, UK, 14-15 March, 1997. Report and abstracts.

Retsas S, Falkson C

Melanoma research.. 1997 April 7 (2):153-73. Epub 1900 01 01.

The low-grade lymphoproliferative disorders.

Eek R, Falkson G

Oncology.. 1997 54 (6):441-58. Epub 1900 01 01.

Granulocyte-colony stimulating factor fails to prevent leucopenia caused by CEMP in elderly patients with aggressive lymphoma.

Nel JS, Falkson CI

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.. 1996 December 86 (12):1564. Epub 1900 01 01.

Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Lancet.. 1996 November 2348 (9036):1189-96. Epub 1900 01 01.

A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer.

Falkson CI, Falkson HC

Annals of oncology : official journal of the European Society for Medical Oncology. 1996 July 7 (5):465-9. Epub 1900 01 01.

Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma.

Falkson CI

American journal of clinical oncology.. 1996 June 19 (3):268-70. Epub 1900 01 01.

A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia.

Hocepied AM, Falkson CI, Falkson G

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.. 1996 May 86 (5):549-50. Epub 1900 01 01.

The low grade lymphoproliferative disorders.

Eek R W; Falkson C I.

Specialist Medicine. 1996; : 14-23, 39.

Cisplatin versus cisplatin plus D-Trp-6-LHRH in the treatment of ovarian cancer: a pilot trial to investigate the effect of the addition of a GnRH analogue to cisplatin.

Falkson CI, Falkson HC, Falkson G

Oncology.. 1996 53 (4):313-7. Epub 1900 01 01.

Granulocyte-macrophage-colony-stimulating factor support in patients with acute non-lymphatic leukemia.

Nel JS, Falkson CI

Oncology.. 1996 53 (6):482-7. Epub 1900 01 01.

Treatment of metastatic malignant melanoma.

Falkson CI

Anti-cancer drugs.. 1995 December 6 (6):709-16. Epub 1900 01 01.

Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.

Falkson CI

Medical oncology.. 1995 March 12 (1):35-40. Epub 1900 01 01.

Antiemetic efficacy of tropisetron in patients failing previous antiemetic therapy.

Falkson CI, Falkson HC

Oncology.. 1995 52 (5):427-31. Epub 1900 01 01.

Reinduction with the same cytostatic treatment in patients with metastatic breast cancer: an Eastern Cooperative Oncology Group study.

Falkson G, Gelman R, Glick J, Falkson CI, Harris J

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 1994 January 12 (1):45-9. Epub 1900 01 01.

Phase II trial of fotemustine in patients with metastatic malignant melanoma.

Falkson CI, Falkson G, Falkson HC

Investigational new drugs.. 1994 12 (3):251-4. Epub 1900 01 01.

FIVB plus GM-CSF in metastatic colorectal cancer.

Falkson CI, Falkson G, Falkson HC, Uys A, Keren-Rosenberg S

Investigational new drugs.. 1994 12 (1):49-52. Epub 1900 01 01.

Recombinant human erythropoietin in the treatment of cancer-related anaemia.

Falkson CI, Keren-Rosenberg S, Uys A, Falkson G, Stevens K, Vermaak WJ

Oncology.. 1994 51 (6):497-501. Epub 1900 01 01.

Combined modality treatment of gastrointestinal cancer.

Falkson G, Falkson CI, Falkson CB

Current opinion in oncology.. 1993 July 5 (4):710-8. Epub 1900 01 01.

New formulation intravenous melphalan in the treatment of patients with metastatic renal cancer.

Falkson CI

Investigational new drugs.. 1993 February 11 (1):93. Epub 1900 01 01.

A randomized trial of mitomycin-C (M) versus mitomycin-C plus high-dose medroxyprogesterone acetate (MMPA) in the treatment of patients with advanced breast cancer.

Falkson CI, Falkson G, Falkson CB, Falkson HC

American journal of clinical oncology.. 1993 February 16 (1):14-7. Epub 1900 01 01.

Postmenopausal breast cancer. Drug therapy in the 1990s.

Falkson CI, Falkson G, Falkson HC

Drugs & aging.. 1993 3 (2):106-21. Epub 1900 01 01.

Cyclophosphamide, doxorubicin and fluorouracil (CAF) plus depo-buserelin in the treatment of premenopausal women with metastatic breast cancer.

Falkson CI, Falkson HC, Falkson G

Annals of oncology : official journal of the European Society for Medical Oncology. 1992 December 3 (10):849-53. Epub 1900 01 01.

Metastatic breast cancer: higher versus low dose maintenance treatment when only a partial response or a no change status is obtained following doxorubicin induction treatment. An Eastern Cooperative Oncology Group study.

Falkson G, Gelman RS, Glick J, Falkson CI, Harris J

Annals of oncology : official journal of the European Society for Medical Oncology. 1992 November 3 (9):768-70. Epub 1900 01 01.

An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.

Falkson G, Hunt M, Borden EC, Hayes JA, Falkson CI, Smith TJ

Investigational new drugs.. 1992 November 10 (4):337-43. Epub 1900 01 01.

New developments in cancer management.

Falkson C I.

Hospital and Specialist Medicine. 1992; 14(2): 16-17.

Prevention of vomiting caused by cytotoxic drugs

Falkson G; Falkson C I.

Cont Medical Education. 1992; 10(12): 2053-2056, 2058, 2060.

Chemotherapy and Interferons in metastatic malignant melanoma: Will they work and why?

Falkson C I.

Cancer Therapy Update. 1992; 12(4).

Current approaches in the management of patients with hepatocellular carcinoma.

Falkson G, Falkson CI

Oncology research.. 1992 4 (3):87-9. Epub 1900 01 01.

Mitomycin C + high-dose medroxyprogesterone versus cyclophosphamide+doxorubicin plus fluorouracil as first-line treatment for metastatic breast cancer.

Falkson CI, Falkson G, Falkson CB, Falkson HC

Oncology.. 1992 49 (6):418-21. Epub 1900 01 01.

Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.

Falkson G, Gelman R, Falkson CI, Glick J, Harris J

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 1991 December 9 (12):2153-61. Epub 1900 01 01.

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.

Falkson CI, Falkson G, Falkson HC

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 1991 August 9 (8):1403-8. Epub 1900 01 01.

Adjuvant therapy now indicated for colorectal carcinoma.

Falkson CI

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.. 1991 June 1579 (12):692. Epub 1900 01 01.

Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin.

Falkson CI, Falkson G, Falkson HC

Annals of oncology : official journal of the European Society for Medical Oncology. 1991 April 2 (4):303-4. Epub 1900 01 01.

Serum Hormone levels in premenopausal women with breast cancer treated with adjuvant CMF or CMF + Buserelin

Voges C W; Falkson C I.

Eur J Cancer. 1991; : 52.

Continuation of Granisetron administration in patients receiving cytostatics.

de Wet M; Falkson C I; Voges C W.

Eur J Cancer. 1991; : 293.

Chemotherapy treatment for carcinomas of the liver, gallbladder and bile duct and pancreas

Falkson C I; Falkson C B; Falkson H C; Falkson G.

Understanding Oncology. 1991; 24(4): 27-28, 29-32, 34.

Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancer.

Falkson CI, Falkson HC, Falkson G

European journal of cancer : official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR).. 1991 27 (10):1208-11. Epub 1900 01 01.

Sister chromatid exchanges in lymphocyte cultures of patients previously treated with dibromodulcitol.

Ansell SM, Jansen van Rensburg CE, Rapoport BL, Gresse P, Cloete EV, van Staden AM, Stevens K, Falkson CI, Falkson G

Oncology.. 1991 48 (3):253-7. Epub 1900 01 01.

High versus low dose granisetron, a selective 5HT3 antagonist, for the prevention of chemotherapy-induced nausea and vomiting.

Falkson HC, Falkson CI, Falkson G

Investigational new drugs.. 1990 November 8 (4):407-9. Epub 1900 01 01.

Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies.

Falkson G, Gelman RS, Leone L, Falkson CI

Cancer.. 1990 October 166 (7):1621-9. Epub 1900 01 01.

Cancer Chemotherapy and Breast Cancer.

Falkson C I; Falkson G; Falkson H C.

Understanding Oncology. 1990; 1(3): 15,17,18.

Are we making progress in the management of cancer?

Falkson CI.

Hospital Medicine. 1990; 12(7): 22-24.

Are we making progress in the management of breast cancer?

Falkson CI.

Cancer Therapy Update. 1990; 10(5).

Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.

Falkson CI, Falkson HC, Falkson G

Investigational new drugs.. 1989 July 7 (2-3):261-7. Epub 1900 01 01.

High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancer.

Falkson CI, Falkson HC, Falkson G

American journal of clinical oncology.. 1988 August 11 (4):431-4. Epub 1900 01 01.

Cyclophosphamide, mitoxantrone, vincristine and prednisone in the treatment of non-Hodgkin's lymphoma.

Vorobiof DA, Terblanche AP, Falkson CI, Falkson G

Oncology.. 1988 45 (5):378-9. Epub 1900 01 01.

Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study.

Falkson G, Gelman RS, Tormey DC, Falkson CI, Wolter JM, Cummings FJ

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 1987 June 5 (6):881-9. Epub 1900 01 01.

Mesothelioma or ovarian carcinoma? A case report.

Falkson CI

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.. 1985 October 2668 (9):676-7. Epub 1900 01 01.

Verslag Reis VSA September/Oktober 1984

Falkson CI.

Geneeskunde. 1985; : 102 103, 105 107.

Oorlewing op langtermyn by pasiënte met Non Hodgkin Limfoom

Falkson G; Falkson C I; Scherman R C; Terblanche A P S.

Geneeskunde. 1984; 26: 323 325,327 328.

Books

Breast Cancer in Women of African Descent. (2005)

Chapter: Adjuvant Therapy of Breast Cancer

Breast Cancer (2003)

Cancer Treatment and Research, Gastrointestinal Oncology (1998)

Chapter: Hepatocellular Carcinoma

MIMS Prescribing Power (1998)

Chapter: Cancer Pain

MIMS Disease Review (1998)

Chapter: Leukaemia.

MIMS Disease Review (1998)

Chapter: Breast Cancer

MIMS Disease Review (1998)

Chapter: Cancer Pain

MIMS Disease Review (1998)

Chapter: Skin Cancer

MIMS Prescribing Power (1996)

Chapter: Cancer Pain

Current Therapy in Hematology - Oncology (1995)

Chapter: Primary Liver Cancer

Manual of Practical Gynecological Oncology (1995)

Chapter: Chemotherapy for gynecological cancer

MIMS Disease Review (First South African Edition) (1995)

Chapter: Breast Cancer

MIMS Disease Review (First South African Edition) (1995)

Chapter: Leukaemia

MIMS Disease Review (First South African Edition) (1995)

Chapter: Lung Cancer

MIMS Disease Review (First South African Edition) (1995)

Chapter: Malignant lymphomas

MIMS Disease Review (First South African Edition), (1995)

Chapter: Skin Cancer

Melanoma: the Disease and its Treatment. (1993)

Handbook of Chemotherapy in Clinical Oncology. (1993)

Chapter: Hepatocarcinoma, Hepatoblastoma

MIMS Disease Index (1993)

Chapter: Breast Cancer

MIMS Disease Index (1993)

Chapter: Leukaemias

MIMS Disease Index (1993)

Chapter: Lung cancer

MIMS Disease Index (1993)

Chapter: Lymphomas, malignant

MIMS Disease Index (1993)

Chapter: Skin cancer.

Medical Management of Breast Cancer (1991)

Chapter: Combination chemotherapy

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.

Ratings

Care provider's discussion of any proposed treatment (options, risks, benefits, etc.)

4.8

Likelihood of recommending this care provider to others

4.8

Explanations the care provider gave you about your problem or condition

4.8

Care provider's efforts to include you in decisions about your care

4.9

Concern the care provider showed for your questions or worries

4.8

Patient Comments

Professional and trustworthy

Dec 21, 2024

Carla Falkson seemed to be in a hurry to finish with me. [...] Not that she was bad, but she was not good. I was not impressed.

Dec 21, 2024

We had a good talk about a troubling medial situation

Nov 29, 2024

Dr. Falkson did not appear prepared for my time with her. It does not engender a great deal of confidence when the greeting is "why are you here?"

Nov 17, 2024

Excellent care

Nov 17, 2024

Dr. Falkson is incredible. She listens, cares, and takes all the time she can with me. I would recommend her to anyone.

Nov 06, 2024

5.0

I have complete confidence in Dr. Falkson. She is compassionate, knowledgeable and is a top notch veteran physician in Rochester.

Oct 15, 2024

5.0

I have always been glad I left [...] and started here

Aug 02, 2024

5.0

Excellent care giver, went about and beyond expectations.

Jul 30, 2024

5.0

EVERYONE at Pluta has been exceptional.I'm confident I am getting the BEST care possible!

Jul 23, 2024

5.0

Dr. Falkson is a phenomenal provider. I trust her implicitly. She always listens to my concerns, and she always answers my questions thoroughly. I highly recommend her. This region is so lucky to have her.

Mar 03, 2024

5.0

Dr. Falkson was very thorough with explaining to me stages of my cancer and options of care. She was very accommodating with providing me an exam room that I would be comfortable in.

Jan 27, 2024

5.0

My experiences with Dr. Falkson have been and continue to be the best I could ever imagine. She's been the pillar of support for me and I couldn't imagine a better caregiver than her. She's given me so much strength and medical help after my stage 4 cancer diagnosis 3 years ago. Her knowledge, concern and demeanor as a physician are unrivaled. I am so happy and blessed she was the oncologist who I received to help me on this journey.

Dec 01, 2023

5.0

Very helpful for major health issue.

Nov 08, 2023

3.8

Good experience but not great

Jun 30, 2023

5.0

Provider explain everything to me the medicine the steps that I have to take for the next procedure towards doing my chemo

Jun 08, 2023

5.0

I have already recommended this team!

May 14, 2023

5.0

Thank you so much for reviewing my tests and helping with next steps!

Mar 31, 2023

5.0

Good

Jan 30, 2023

Very good experience

Jan 18, 2023

5.0

I have already referred a patient to this physician. [...] Grateful to have a doc that seems to be a strong advocate for me.

Jan 07, 2023

4.6

Dr. Falkson and her team have always taken the time to explain my health issues and options along with the risks and benefits. They have included me in the decision making to the extent possible and always make certain that I both understand and agree with my plan of care. I am so fortunate to have such a wonderful care team.

Nov 14, 2022

3.0

When I mentioned that was not sleeping well, rather than compassion, or a solution I was told how little sleep she was experiencing.

Oct 28, 2022

I think dr. Falkson is the best

Oct 25, 2022

4.6

My doctor overruled my wishes - which was for my own good. I'm so glad she did!

Aug 30, 2022

Dr. Falkson has been excellent

Jul 23, 2022

Dr. Falkson always makes sure to discuss all the above aspects of my health conditions, clearly and fully with me on every zoom appointment. I would highly recommend Dr, Falkson and her staff to anyone needing care for breast cancer.

Jun 30, 2022

5.0

Dr. Falkson is outstanding In her field. I would recommend her with no hesitations.

May 14, 2022

Dr Falkson is always very attentive and completely answers and questions I have.

Apr 16, 2022

She was amazing and interesting

Mar 28, 2022

Dr. Falkson was excellent in all ways.

Feb 05, 2022